Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jan;37(1):123–125. doi: 10.1128/aac.37.1.123

In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia.

C Lewin 1, C Doherty 1, J Govan 1
PMCID: PMC187617  PMID: 8431009

Abstract

In a study of 110 Pseudomonas cepacia isolates from patients without cystic fibrosis, the in vitro potencies of three new compounds, meropenem, PD 127391, and PD 131628, were comparable to those of ceftazidime and ciprofloxacin and exceeded those of chloramphenicol and co-trimoxazole. The MICs of ceftazidime, ciprofloxacin, meropenem, and the PD compounds for 90% of strains tested were < or = 4 micrograms/ml, whereas they were 32 micrograms/ml for chloramphenicol and co-trimoxazole. Data for 20 isolates from patients with cystic fibrosis indicated that the isolates were less susceptible to all seven antibiotics tested, with the most active compounds being meropenem and PD 127391.

Full text

PDF
123

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronoff S. C., Klinger J. D. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrob Agents Chemother. 1984 Feb;25(2):279–280. doi: 10.1128/aac.25.2.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baltimore R. S., Radnay-Baltimore K., von Graevenitz A., Dolan T. F. Occurrence of nonfermentative gram-negative rods other than Pseudomonas aeruginosa in the respiratory tract of children with cystic fibrosis. Helv Paediatr Acta. 1982;37(6):547–554. [PubMed] [Google Scholar]
  3. Beckman W., Lessie T. G. Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source. J Bacteriol. 1979 Dec;140(3):1126–1128. doi: 10.1128/jb.140.3.1126-1128.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Domagala J. M., Heifetz C. L. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother. 1991 Jan;35(1):141–146. doi: 10.1128/aac.35.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Edwards J. R., Turner P. J., Wannop C., Withnell E. S., Grindey A. J., Nairn K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother. 1989 Feb;33(2):215–222. doi: 10.1128/aac.33.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gilligan P. H., Gage P. A., Bradshaw L. M., Schidlow D. V., DeCicco B. T. Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol. 1985 Jul;22(1):5–8. doi: 10.1128/jcm.22.1.5-8.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gold R., Overmeyer A., Knie B., Fleming P. C., Levison H. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis. 1985 Mar-Apr;4(2):172–177. doi: 10.1097/00006454-198503000-00012. [DOI] [PubMed] [Google Scholar]
  8. Goldmann D. A., Klinger J. D. Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J Pediatr. 1986 May;108(5 Pt 2):806–812. doi: 10.1016/s0022-3476(86)80749-1. [DOI] [PubMed] [Google Scholar]
  9. Govan J. R., Harris G. Typing of Pseudomonas cepacia by bacteriocin susceptibility and production. J Clin Microbiol. 1985 Oct;22(4):490–494. doi: 10.1128/jcm.22.4.490-494.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Holmes B. The identification of Pseudomonas cepacia and its occurrence in clinical material. J Appl Bacteriol. 1986 Oct;61(4):299–314. doi: 10.1111/j.1365-2672.1986.tb04291.x. [DOI] [PubMed] [Google Scholar]
  11. Isles A., Maclusky I., Corey M., Gold R., Prober C., Fleming P., Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984 Feb;104(2):206–210. doi: 10.1016/s0022-3476(84)80993-2. [DOI] [PubMed] [Google Scholar]
  12. Jones R. N., Barry A. L., Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):9–29. doi: 10.1093/jac/24.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  13. Kilbane J. J., Chatterjee D. K., Chakrabarty A. M. Detoxification of 2,4,5-trichlorophenoxyacetic acid from contaminated soil by Pseudomonas cepacia. Appl Environ Microbiol. 1983 May;45(5):1697–1700. doi: 10.1128/aem.45.5.1697-1700.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. King A., Boothman C., Phillips I. The in-vitro activity of PD127,391, a new quinolone. J Antimicrob Chemother. 1988 Aug;22(2):135–141. doi: 10.1093/jac/22.2.135. [DOI] [PubMed] [Google Scholar]
  15. Klinger J. D., Thomassen M. J. Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis. 1985 Mar;3(2):149–158. doi: 10.1016/0732-8893(85)90025-2. [DOI] [PubMed] [Google Scholar]
  16. Kropp H., Sundelof J. G., Hajdu R., Kahan F. M. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982 Jul;22(1):62–70. doi: 10.1128/aac.22.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nord C. E., Wadström T., Wretlind B. Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia. Antimicrob Agents Chemother. 1974 Oct;6(4):521–523. doi: 10.1128/aac.6.4.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Prince A. Antibiotic resistance of Pseudomonas species. J Pediatr. 1986 May;108(5 Pt 2):830–834. doi: 10.1016/s0022-3476(86)80753-3. [DOI] [PubMed] [Google Scholar]
  19. Rabkin C. S., Jarvis W. R., Anderson R. L., Govan J., Klinger J., LiPuma J., Martone W. J., Monteil H., Richard C., Shigeta S. Pseudomonas cepacia typing systems: collaborative study to assess their potential in epidemiologic investigations. Rev Infect Dis. 1989 Jul-Aug;11(4):600–607. doi: 10.1093/clinids/11.4.600. [DOI] [PubMed] [Google Scholar]
  20. Rosenstein B. J., Hall D. E. Pneumonia and septicemia due to Pseudomonas cepacia in a patient with cystic fibrosis. Johns Hopkins Med J. 1980 Nov;147(5):188–189. [PubMed] [Google Scholar]
  21. Santos-Ferreira M. O., Vital J. O. In-vitro antibacterial activity of imipenem compared with four other beta-lactam antibiotics (ceftazidime, cefotaxime, piperacillin and azlocillin) against 828 separate clinical isolates from a Portuguese hospital. J Antimicrob Chemother. 1986 Dec;18 (Suppl E):23–26. doi: 10.1093/jac/18.supplement_e.23. [DOI] [PubMed] [Google Scholar]
  22. Tablan O. C., Chorba T. L., Schidlow D. V., White J. W., Hardy K. A., Gilligan P. H., Morgan W. M., Carson L. A., Martone W. J., Jason J. M. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr. 1985 Sep;107(3):382–387. doi: 10.1016/s0022-3476(85)80511-4. [DOI] [PubMed] [Google Scholar]
  23. Tablan O. C., Martone W. J., Doershuk C. F., Stern R. C., Thomassen M. J., Klinger J. D., White J. W., Carson L. A., Jarvis W. R. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest. 1987 Apr;91(4):527–532. doi: 10.1378/chest.91.4.527. [DOI] [PubMed] [Google Scholar]
  24. Taylor R. F., Gaya H., Hodson M. E. Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia. J Antimicrob Chemother. 1992 Mar;29(3):341–344. doi: 10.1093/jac/29.3.341. [DOI] [PubMed] [Google Scholar]
  25. Wise R., Andrews J. M., Danks G. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother. 1984 Mar;13(3):237–244. doi: 10.1093/jac/13.3.237. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES